With plans to bring su­r­u­fa­tinib state­side, Chi-Med vast­ly scales up man­u­fac­tur­ing with new Chi­nese plant

Hutchi­son Chi­na MediTech, or Chi-Med, is at­tempt­ing to break new ground by bring­ing its in­ter­nal­ly de­vel­oped on­col­o­gy can­di­date su­r­u­fa­tinib to US shores—which would make it just the sec­ond Chi­nese-de­vel­oped drug to do so. With that goal in mind, the firm is vast­ly scal­ing up its man­u­fac­tur­ing op­er­a­tions for a planned glob­al push.

Chi-Med is build­ing out a new large-scale man­u­fac­tur­ing fa­cil­i­ty in Zhangjiang, Shang­hai, that will to­tal 592,000 square feet of floor space and boost the com­pa­ny’s pro­duc­tion ca­pac­i­ty by more than 600% past its cur­rent op­er­a­tions in Suzhou.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER